BeStock  
Stocks › Biotechnology › EWTX

Edgewise Therapeutics EWTX

US equityMarket cap rank #2154Biotechnology
$39.91 −$1.27 (-3.07%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $39.91 0.00%
Open$40.81
Prev close$41.17
Day range$39.71 – $41.41
Volume1.19M
Market cap$4.37B
P/E (TTM)4.8
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$46.14M+1.5% YoY
Net profit$1.17B+2,967.6% YoY
Diluted EPS$9.65+2,574.4% YoY
Free cash flow-$78.31M-124.6% YoY
Operating cash flow-$78.29M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-39.7MDec '24$-40.8MMar '25$-36.1MJun '25$-40.7MSep '25$-50.2MDec '25$-49.0MMar '26$-57.3MJun '26$1.2BSep '26

Diluted EPS by quarter

-0.42Dec '24-0.43Mar '25-0.34Jun '25-0.39Sep '25-0.47Dec '25-0.46Mar '26-0.53Jun '269.65Sep '26

Free cash flow by quarter

$-27.2MDec '24$-37.9MMar '25$-32.6MJun '25$-34.9MSep '25$-38.7MDec '25$-42.8MMar '26$-42.5MJun '26$-78.3MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity92.1%
Return on assets85.4%
Return on invested capital90.1%
Current ratio12.30
Liabilities / assets8.3%
Cash & investments$1.74B
Total debt$2.36M
Net cash (debt)$1.74B

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $46.14M $61.94M $54.12M $191.41M $55.98M
Selling and Admin Expenses $14.57M $14.40M $11.46M $40.02M $12.39M
-General & Admin Expense $14.57M $14.40M $11.46M $40.02M $12.39M
Research & Development $31.58M $47.55M $42.65M $151.39M $43.59M
Operating Profit -$46.14M -$61.94M -$54.12M -$191.41M -$55.98M
Net Non-Operating Interest Income (Expense) $16.50M $4.62M $5.10M $23.61M $5.76M
Non-Operating Interest Income $16.50M $4.62M $5.10M $23.61M $5.76M
Other Income (Expense) $1.35B – – – –
Special Income (Charges) $1.35B – – – –
-Gain on Sale Of Business $1.35B – – – –
Other Non-Operating Income (Expenses) $3.07M – – – –
Pretax Profit $1.32B -$57.33M -$49.01M -$167.80M -$50.22M
Tax $155.33M – – – –
Net Profit $1.17B -$57.33M -$49.01M -$167.80M -$50.22M
Profit from Continuing Operations $1.17B -$57.33M -$49.01M -$167.80M -$50.22M
Net Income to Parent Company $1.17B -$57.33M -$49.01M -$167.80M -$50.22M
Net Income to Common Stockholders $1.17B -$57.33M -$49.01M -$167.80M -$50.22M
Basic EPS $10.71 -$0.53 -$0.46 -$1.63 -$0.47
Diluted EPS $9.65 -$0.53 -$0.46 -$1.63 -$0.47

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.78B $479.69M $518.52M $552.60M $552.60M
Total Current Assets $1.77B $471.52M $509.79M $543.39M $543.39M
Cash and Cash Equivalents & Short-Term Investments $1.74B $460.71M $499.56M $530.11M $530.11M
-Cash and Cash Equivalents $68.68M $72.32M $33.21M $61.15M $61.15M
-Short Term Investments $1.68B $388.39M $466.35M $468.96M $468.96M
Other Current Assets $28.58M $6.45M $10.23M $13.28M $13.28M
Total Non-Current Assets $7.55M $8.17M $8.73M $9.22M $9.22M
Net PPE $7.55M $8.17M $8.73M $9.22M $9.22M
-Gross PPE $15.93M $16.02M $16.04M $15.99M $15.99M
-Accumulated Depreciation -$8.38M -$7.85M -$7.31M -$6.77M -$6.77M
Total Liabilities $147.35M $31.61M $25.32M $30.35M $30.35M
Total Current Liabilities $144.11M $29.04M $22.54M $27.37M $27.37M
Payables $118.54M $4.67M $7.29M $6.01M $6.01M
-Accounts Payable $9.64M $4.67M $7.29M $6.01M $6.01M
-Total Tax Payable $108.90M – – – –
Current Accrued Expenses $10.56M $5.19M $8.56M $7.92M $7.92M
Short-Term Debt and Capital Lease Obligation $1.03M $1.02M $1.02M $1.01M $1.01M
-Current Capital Lease Obligation $1.03M $1.02M $1.02M $1.01M $1.01M
Current Deferred Liabilities $5.18M – – – –
Total Non-Current Liabilities $3.25M $2.57M $2.78M $2.98M $2.98M
Long Term Debt and Capital Lease Obligation $2.36M $2.57M $2.78M $2.98M $2.98M
-Long Term Capital Lease Obligation $2.36M $2.57M $2.78M $2.98M $2.98M
Other Non-Current Liabilities $888,000.00 – – – –
Total Equity $1.63B $448.08M $493.20M $522.26M $522.26M
Stockholders' Equity $1.63B $448.08M $493.20M $522.26M $522.26M
Capital Stock $10,000.00 $10,000.00 $10,000.00 $10,000.00 $10,000.00
-Common Stock $10,000.00 $10,000.00 $10,000.00 $10,000.00 $10,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.12B $1.10B $1.09B $1.07B $1.07B
Retained Earnings $513.44M -$652.71M -$595.38M -$546.37M -$546.37M
Gains/Losses Not Affecting Retained Earnings -$5.60M -$500,000.00 -$252,000.00 $677,000.00 $677,000.00
Other Current Liabilities – $9.59M – – –

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$78.29M -$42.47M -$42.54M -$143.82M -$38.59M
Net cash flow from continuing operations -$78.29M -$42.47M -$42.54M -$143.82M -$38.59M
Net Income from Continuing Operations $1.17B -$57.33M -$49.01M -$167.80M -$50.22M
Depreciation & Depletion & Amortization $590,000.00 $597,000.00 $590,000.00 $2.27M $575,000.00
Change in Working Capital $97.20M $5.71M -$1.82M -$5.37M $2.66M
-Change in Prepaid Assets -$19.32M -$579,000.00 $3.05M -$7.96M -$2.72M
-Change in Payables and Accrued Expense $116.72M $6.49M -$4.67M $3.34M $5.57M
-Change in Other Current Liabilities -$206,000.00 -$203,000.00 -$196,000.00 -$748,000.00 -$193,000.00
Net cash flow from investing $59.68M $78.49M $2.43M -$32.79M $49.76M
Net Cash Flow from Continuing Investing Activities $59.68M $78.49M $2.43M -$32.79M $49.76M
Net PPE Purchase and Sale -$17,000.00 -$32,000.00 -$260,000.00 -$256,000.00 -$73,000.00
Net Investment Purchase and Sale -$1.29B $78.52M $2.69M -$32.53M $49.84M
Financing Cash Flow $14.98M $3.09M $12.17M $196.09M $3.98M
Net Cash Flow from Continuing Financing Activities $14.98M $3.09M $12.17M $196.09M $3.98M
Net Common Stock Issuance $0.00 – – $187.36M $0.00
Proceeds from Stock Option Exercised $14.98M $3.09M $12.17M $8.73M $3.98M
Ending Cash Balance $68.68M $72.32M $33.21M $61.15M $61.15M
Net Change in Cash -$3.64M $39.11M -$27.94M $19.48M $15.15M
Beginning Cash Balance $72.32M $33.21M $61.15M $41.67M $46.00M
Free Cash Flow -$78.31M -$42.50M -$42.80M -$144.07M -$38.67M

Discussion

No comments yet — be the first to weigh in on EWTX.

Sign in to join the discussion.

Scroll to Top